New drug combo shows promise in multiple myeloma fight

NCT ID NCT02405364

Completed Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Apr 16, 2026 · Last updated Apr 30, 2026 · Updated 4 times

Summary

This study tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 adults aged 65 or younger with newly diagnosed multiple myeloma. The goal was to see how many patients achieved a very deep remission. The results will help decide if this approach should be tested in larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CHRU Dijon

Dijon, France
CHRU Hôtel Dieu

Nantes, France
CHU Grenoble

Grenoble, France
CHU Henri Mondor

Créteil, France
CHU de Toulouse

Toulouse, 31000, France
Hôpital Bretonneau

Tours, France
Hôpital Claude Huriez

Lille, France
Hôpital Saint-Antoine

Paris, France
Hôpital de Hautepierre

Strasbourg, France
Hôpital de Pontchaillou

Rennes, France
University hospital of Toulouse

Toulouse, 31000, France

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA